Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...
BioSpace11h
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Le Lézard12h
Brands Embrace Emotional Engagement as Spending Grows
While consumer spending is high, so is business investment, according to  Deloitte  ? which can make differentiating amongst competitors harder than ever with significant gains or losses at ...
Le Lézard13h
VANTAGE FOUNDATION PARTNERS WITH SOS CHILDREN'S VILLAGES PHILIPPINES TO EMPOWER VULNERABLE CHILDREN AND FAMILIES
Vantage Foundation proudly announces its partnership with SOS Children's Villages Philippines, a NGO committed to providing ...
Seeking Alpha on MSN12h
Biogen, Eisai Alzheimer’s drug review delayed in EU
Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
AbbVie Surges 5% As Immunology Powerhouses Skyrizi And Rinvoq Continue To Dominate
AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...